Target intelligence / Profile preview

Adenovirus-derived peptide-Human Leukocyte Antigen complex (Adv-peptide-HLA complex) (Adv-peptide-HLA complex)

Target
Adv-peptide-HLA complex
Molecular classification
Peptide-MHC complex, Antigen-presenting complex, Major Histocompatibility Complex Class I
01

Overview

The Adenovirus-derived peptide-Human Leukocyte Antigen (HLA) complex is a molecular assembly consisting of a short viral peptide fragment, typically derived from the Adenovirus Hexon protein, bound within the groove of an HLA class I molecule on the surface of infected cells (PubMed: 15126550). This complex serves as the essential recognition unit for the host's cellular immune system, specifically for CD8+ cytotoxic T-lymphocytes (CTLs) via their T-cell receptors (TCRs) (PubMed: 16461632). In clinical settings, particularly for immunocompromised patients such as those undergoing hematopoietic stem cell transplantation, this complex is a critical therapeutic target for adoptive T-cell therapies and TCR-engineered cells designed to restore viral immunity (PubMed: 24661910). The interaction between the TCR and the peptide-HLA complex triggers the destruction of the infected cell, thereby controlling the viral spread (PubMed: 18451253). Understanding the specific HLA alleles, such as HLA-A*01 or HLA-B*07, and the immunodominant peptides involved is vital for the development of precision immunotherapies and vaccines against adenovirus-related pathologies (PubMed: 21148333). Therapeutic strategies often involve the infusion of virus-specific T-cells (VSTs) that have been expanded ex vivo to recognize these specific complexes. Challenges in targeting this complex include viral evasion strategies, such as the downregulation of HLA molecules by the virus to avoid detection. Additionally, ensuring the specificity of the TCR to avoid cross-reactivity with human self-peptides is a primary safety concern in the development of TCR-T therapies.

Other names
Adenoviral peptide-MHC complexAdv-pMHCAdenovirus antigen-HLA complexAdenovirus peptide-major histocompatibility complexAdenovirus hexon peptide-HLA complexAdv-pHLA
02

Mechanism of action

The complex acts as a ligand for T-cell receptors (TCRs) on CD8+ cytotoxic T-lymphocytes, triggering intracellular signaling cascades that lead to the release of perforins and granzymes, ultimately resulting in the apoptosis of the adenovirus-infected cell (PubMed: 16461632).

03

Biological functions

Antigen presentationT-cell activationImmune recognitionCellular immunityCytotoxic T-lymphocyte response
04

Disease associations

Adenovirus infectionInfection in immunocompromised patientsDisseminated adenovirus disease
05

Safety considerations

Cross-reactivity with self-antigens (molecular mimicry)Cytokine release syndrome (CRS)HLA downregulation by viral evasion mechanismsGraft-versus-host disease (GvHD) in the context of allogeneic T-cell transfer
06

Interacting drugs

Posoleucel (Viralym-M)

3 more in the full profile.

07

Biomarkers

HLA-A*01:01HLA-A*02:01HLA-B*07:02HLA-B*35:01Adenovirus Hexon protein expressionAdenovirus viral load (qPCR)

Beyond the preview

Go deeper on Adenovirus-derived peptide-Human Leukocyte Antigen complex (Adv-peptide-HLA complex) (Adv-peptide-HLA complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenovirus-derived peptide-Human Leukocyte Antigen complex (Adv-peptide-HLA complex) (Adv-peptide-HLA complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call